RxDoctor Payments Data

Hadleigh Trevino

Family · Chattanooga, TNNPI 1629452297

Payments from drug & device makers

$3,008in general payments, 2019–2025

Across 113 payments — averaging $26.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Sumitomo Pharma America, Inc.$478
  • C. R. Bard, Inc. & Subsidiaries$294
  • AbbVie$172
  • Boston Scientific$98
  • Genentech USA, Inc.$89
  • plus $101 from 5 others

What the payments were for

  • Travel & lodging$1,34645%
  • Food & beverage$1,66255%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Axonics, Inc.11$1,778
Sumitomo Pharma America, Inc.64$478
C. R. Bard, Inc. & Subsidiaries10$294
AbbVie9$172
Boston Scientific1$98
Genentech USA, Inc.13$89
Profound Medical Corp.1$30
Dentsply IH AB1$20
ABC Home Medical Supply, Inc.1$19
Urogen Pharma, Inc.1$17
Medtronic1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,008 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$30,515
Medicare patients
186
Services billed
804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron153$99,107
MyrbetriqMirabegron60$30,774
Trospium Chloride ErTrospium Chloride60$13,668
Estradiol193$12,591
Methenamine Hippurate64$4,496
Tolterodine Tartrate ErTolterodine Tartrate17$1,466
Trospium Chloride29$1,174
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst73$762
Oxybutynin Chloride ErOxybutynin Chloride22$580
Solifenacin Succinate15$354
Tamsulosin Hcl34$328
Cephalexin44$287
Fluconazole17$72
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim17$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$478$99,107153 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.

Other family in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →